Empajent 10/5 is a fixed-dose combination tablet containing **Empagliflozin (SGLT2 inhibitor)** and **Linagliptin (DPP-4 inhibitor)**, produced by Alhavi Pharmaceutical — the first manufacturer of this combination in Iran.
It is used to control blood glucose levels in adults with type 2 diabetes mellitus.
The complementary mechanisms of both active ingredients help improve glycemic control — Empagliflozin by increasing urinary glucose excretion, and Linagliptin by enhancing insulin secretion and reducing hepatic glucose production.
Empajent is available in two strengths: **10/5 mg** and **25/5 mg** tablets.
Empajent 10/5 (Empagliflozin + Linagliptin)
Dosage form: Tablet
Empajent is indicated for:
• Control of blood glucose levels in adults with type 2 diabetes mellitus requiring combination therapy with Empagliflozin and Linagliptin
• Can be used as an adjunct to diet and exercise, either alone or with other antidiabetic agents
This dual mechanism enhances glycemic control by promoting urinary glucose excretion and improving pancreatic insulin response.
• Recommended dose (10/5 mg): one tablet once daily
• Can be taken in the morning, with or without food
• Swallow the tablet whole with water — do not crush or chew
• Continue regular blood glucose monitoring and follow dietary and exercise recommendations
• Use under medical supervision, especially in patients with kidney or liver impairment